<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; 2016</title>
	<atom:link href="http://www.tapanray.in/tag/2016/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Patient Services: No Longer An Optional Competitive Driver</title>
		<link>http://www.tapanray.in/patient-services-no-longer-an-optional-competitive-driver/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patient-services-no-longer-an-optional-competitive-driver</link>
		<comments>http://www.tapanray.in/patient-services-no-longer-an-optional-competitive-driver/#comments</comments>
		<pubDate>Mon, 19 Sep 2016 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[Accenture]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[optional]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[professionals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7821</guid>
		<description><![CDATA[The emerging global trend of patients’ demand for greater engagement in their treatment decision making process, could well be a game changer in the prescription demand generation process for pharma brands, even in India, and in not too distant future. &#8230; <a href="http://www.tapanray.in/patient-services-no-longer-an-optional-competitive-driver/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patient-services-no-longer-an-optional-competitive-driver/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>At The Indian IPR Front: ‘Ground Control, There’s No Major Storm’</title>
		<link>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=at-the-indian-ipr-front-ground-control-theres-no-major-storm</link>
		<comments>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/#comments</comments>
		<pubDate>Mon, 05 Sep 2016 00:00:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[2016 Special 301 Report]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[4-5]]></category>
		<category><![CDATA[Arvind]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[G 20]]></category>
		<category><![CDATA[ground]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Major]]></category>
		<category><![CDATA[Niti Aayog]]></category>
		<category><![CDATA[Panagariya]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[September]]></category>
		<category><![CDATA[Sherpa]]></category>
		<category><![CDATA[storm]]></category>
		<category><![CDATA[Summit]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USIBC]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7794</guid>
		<description><![CDATA[The incessant pressure of the developing countries on India, from 2005 to date, to include various restrictive conditions in the Indian Patents Act 2005, still continue. This demand spans across the inclusion of even those provisions, which many experts term &#8230; <a href="http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/at-the-indian-ipr-front-ground-control-theres-no-major-storm/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma In 2016 Rio Olympics</title>
		<link>http://www.tapanray.in/pharma-in-2016-rio-olympics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-in-2016-rio-olympics</link>
		<comments>http://www.tapanray.in/pharma-in-2016-rio-olympics/#comments</comments>
		<pubDate>Mon, 29 Aug 2016 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[ads]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Olympics]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Rio]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7785</guid>
		<description><![CDATA[On August 4, 2016, the ‘Adweek’ &#8211; a well-known weekly American advertising-trade publication, reported that even a day before the games began, the national ad sales revenue of just one major network in ‘2016 Rio Olympics’ had set a new &#8230; <a href="http://www.tapanray.in/pharma-in-2016-rio-olympics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-in-2016-rio-olympics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Drug Safety Concern: “Whistleblower’s Intention Should Be Nationalistic”</title>
		<link>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic</link>
		<comments>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/#comments</comments>
		<pubDate>Mon, 14 Mar 2016 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[Anti-nationalistic]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CDA]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dinesh]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IPO]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Office]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thakur]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Whistleblower]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7529</guid>
		<description><![CDATA[In the recent weeks, three significant developments related to the Pharmaceutical Industry in India, have triggered rejuvenated concerns in the following critical areas:  A. Overall drug safety standards in the country B.  Self serving interest, rather than patients’ interest, dominate &#8230; <a href="http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-drug-safety-concern-whistleblowers-intention-should-be-nationalistic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>2015: Pharma Industry Achieved Some, Could Achieve Some More</title>
		<link>http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=2015-pharma-industry-achieved-some-could-achieve-some-more</link>
		<comments>http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/#comments</comments>
		<pubDate>Mon, 04 Jan 2016 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[achieved]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[Google]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[Novo Nordisk]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research. delivery]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[smart]]></category>
		<category><![CDATA[Social media]]></category>
		<category><![CDATA[Some]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7378</guid>
		<description><![CDATA[Wish You And All Your Near And Dear Ones Peace, Happiness, Good Health And Prosperity in The Brand New Year 2016  The year 2015 witnessed several noteworthy developments in the pharma industry, just as many other years before. That said, &#8230; <a href="http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/2015-pharma-industry-achieved-some-could-achieve-some-more/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Wide Gap Between Health Care Needs, And Delivery: Is The Bridge Still Too Far?</title>
		<link>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far</link>
		<comments>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/#comments</comments>
		<pubDate>Mon, 28 Dec 2015 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[28]]></category>
		<category><![CDATA[Ayog]]></category>
		<category><![CDATA[bridge]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[far]]></category>
		<category><![CDATA[February]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[healtrh]]></category>
		<category><![CDATA[inequity]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[Malnutrition]]></category>
		<category><![CDATA[mortality]]></category>
		<category><![CDATA[needs]]></category>
		<category><![CDATA[Niti]]></category>
		<category><![CDATA[Paper]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[wide]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7353</guid>
		<description><![CDATA[“Health inequities which abound in India must be corrected through investments in a robust primary health care system,&#8221; said Professor K Srinath Reddy, chairman, Public Health Foundation of India (PHFI), not too long ago. The equity gap between health care &#8230; <a href="http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/wide-gap-between-health-care-needs-and-delivery-is-the-bridge-still-too-far/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Union Budget Proposal 2015-16 of India : Is Pharma Industry Now Out of Focus?</title>
		<link>http://www.tapanray.in/union-budget-proposal-2015-16-of-india-is-pharma-industry-now-out-of-focus/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=union-budget-proposal-2015-16-of-india-is-pharma-industry-now-out-of-focus</link>
		<comments>http://www.tapanray.in/union-budget-proposal-2015-16-of-india-is-pharma-industry-now-out-of-focus/#comments</comments>
		<pubDate>Mon, 02 Mar 2015 12:04:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[16]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[out of focus]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[proposal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6421</guid>
		<description><![CDATA[Budget Expectations: Overall expectations of the Pharma Industry in India from the Union Budget perspective was very modest this year. The key areas were as follows: - To encourage  innovation, in-house R&#38;D exemption limit was expected to be raised from &#8230; <a href="http://www.tapanray.in/union-budget-proposal-2015-16-of-india-is-pharma-industry-now-out-of-focus/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/union-budget-proposal-2015-16-of-india-is-pharma-industry-now-out-of-focus/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Patient-Centric State Initiative To Revolutionize Disease Treatment</title>
		<link>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-patient-centric-state-initiative-to-revolutionize-disease-treatment</link>
		<comments>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/#comments</comments>
		<pubDate>Mon, 09 Feb 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2016]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cardiovascular]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[Connect]]></category>
		<category><![CDATA[DCAT]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[ethical]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Pao]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Richard]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Smith]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[William]]></category>
		<category><![CDATA[‘Moonshot’ Medicine Will Let Us Down]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6374</guid>
		<description><![CDATA[In his State of the Union address, just before the recent visit to India in January 2015, President Barack Obama articulated the need to develop &#8220;Precision Medicine&#8221; in his country – a bold, giant and perhaps unprecedented State initiative to &#8230; <a href="http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-patient-centric-state-initiative-to-revolutionize-disease-treatment/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
